NICE confirms recommendation for Soliris for aHUS treatment- Alexion
The National Institute for Health and Care Excellence (NICE) has now published a Final Appraisal Determination for Soliris (eculizumab) from Alexion, for Haemolytic Uraemic Syndrome (aHUS) and confirms its use under a new programme designed to assess highly-specialised technologies which may benefit people with very rare diseases at a high price.The Institute�s Highly Specialised Technologies Evaluation Committee has recommended that Soliris be commissioned for all patients with the disease, securing life-long access to the first and only available treatment for the condition. Around 200 people in England are affected by aHUS.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.